Nigel Parker

1.5k total citations
20 papers, 597 citations indexed

About

Nigel Parker is a scholar working on Surgery, Molecular Biology and Oncology. According to data from OpenAlex, Nigel Parker has authored 20 papers receiving a total of 597 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Surgery, 10 papers in Molecular Biology and 10 papers in Oncology. Recurrent topics in Nigel Parker's work include Bladder and Urothelial Cancer Treatments (10 papers), Virus-based gene therapy research (7 papers) and Cancer Immunotherapy and Biomarkers (6 papers). Nigel Parker is often cited by papers focused on Bladder and Urothelial Cancer Treatments (10 papers), Virus-based gene therapy research (7 papers) and Cancer Immunotherapy and Biomarkers (6 papers). Nigel Parker collaborates with scholars based in Finland, United States and United Kingdom. Nigel Parker's co-authors include Seppo Ylä‐Herttuala, Thomas Wirth, Hanna P. Lesch, Hanna Leinonen, Tommi Heikura, Igor Oruetxebarria, Sharada Mokkapati, David J. McConkey, Colin P. Dinney and Robert A. Shaw and has published in prestigious journals such as Journal of Clinical Oncology, Scientific Reports and The Journal of Urology.

In The Last Decade

Nigel Parker

19 papers receiving 568 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nigel Parker Finland 8 451 284 120 49 43 20 597
Anais K. Amaya Australia 6 597 1.3× 449 1.6× 107 0.9× 55 1.1× 54 1.3× 8 772
Wenxin Cai China 6 773 1.7× 168 0.6× 104 0.9× 57 1.2× 23 0.5× 9 950
Jamie L. Shirley United States 7 562 1.2× 448 1.6× 192 1.6× 39 0.8× 85 2.0× 13 824
Alireza Shahryari Iran 10 497 1.1× 138 0.5× 106 0.9× 57 1.2× 13 0.3× 21 674
Natalie J Ward United Kingdom 9 379 0.8× 321 1.1× 86 0.7× 34 0.7× 68 1.6× 11 539
Giang N. Nguyen United States 8 424 0.9× 328 1.2× 122 1.0× 19 0.4× 54 1.3× 10 624
Heechung Kwon South Korea 14 235 0.5× 194 0.7× 118 1.0× 41 0.8× 20 0.5× 21 571
Giulia Pavani United States 15 783 1.7× 459 1.6× 187 1.6× 18 0.4× 79 1.8× 33 1.1k
Mark Lyons Ireland 9 286 0.6× 222 0.8× 107 0.9× 21 0.4× 75 1.7× 11 505
Cinnamon L Hardee United States 7 275 0.6× 168 0.6× 137 1.1× 53 1.1× 21 0.5× 10 438

Countries citing papers authored by Nigel Parker

Since Specialization
Citations

This map shows the geographic impact of Nigel Parker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nigel Parker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nigel Parker more than expected).

Fields of papers citing papers by Nigel Parker

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nigel Parker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nigel Parker. The network helps show where Nigel Parker may publish in the future.

Co-authorship network of co-authors of Nigel Parker

This figure shows the co-authorship network connecting the top 25 collaborators of Nigel Parker. A scholar is included among the top collaborators of Nigel Parker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nigel Parker. Nigel Parker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Martini, Alberto, Ganiraju C. Manyam, Yan Chen, et al.. (2024). Single-cell RNA sequencing analysis identifies acute changes in the tumor microenvironment induced by interferon α gene therapy in a murine bladder cancer model. Frontiers in Immunology. 15. 1387229–1387229. 2 indexed citations
2.
Narayan, Vikram M., Sharada Mokkapati, Alberto Martini, et al.. (2024). Urinary minimal residual disease detection predicts recurrence in BCG-unresponsive NIMBC and quantifies molecular response to nadofaragene firadenovec.. Journal of Clinical Oncology. 42(4_suppl). 635–635.
3.
Mitra, Anirban P., Sharada Mokkapati, Tanner Miest, et al.. (2022). MP54-05 EVALUATING INTRAVESICAL NADOFARAGENE FIRADENOVEC AND IMMUNE CHECKPOINT BLOCKADE COMBINATION THERAPY IN BCG-UNRESPONSIVE NON-MUSCLE-INVASIVE BLADDER CANCER: EVIDENCE FROM A PHASE 3 TRIAL. The Journal of Urology. 207(Supplement 5). 1 indexed citations
4.
Narayan, Vivek, Stephen A. Boorjian, Badrinath R. Konety, et al.. (2021). Subgroup analyses of the phase 3 study of intravesical nadofaragene firadenovec in patients with high-grade, BCG-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC). European Urology. 79. S1026–S1027. 1 indexed citations
5.
6.
Gurvich, Olga L., Katja A. Puttonen, Aubrey Bailey, et al.. (2020). Transcriptomics uncovers substantial variability associated with alterations in manufacturing processes of macrophage cell therapy products. Scientific Reports. 10(1). 14049–14049. 23 indexed citations
7.
Leinonen, Hanna, et al.. (2020). Benchmarking of Scale-X Bioreactor System in Lentiviral and Adenoviral Vector Production. Human Gene Therapy. 31(5-6). 376–384. 19 indexed citations
8.
Oruetxebarria, Igor, Hanna Leinonen, Tommi Heikura, et al.. (2020). Development of Large-Scale Downstream Processing for Lentiviral Vectors. Molecular Therapy — Methods & Clinical Development. 17. 717–730. 49 indexed citations
9.
Mokkapati, Sharada, Andrea Kokorovic, Vikram M. Narayan, et al.. (2020). Lentiviral interferon with immune checkpoint blockade: A novel method for gene therapy in bladder cancer.. Journal of Clinical Oncology. 38(5_suppl). 33–33. 3 indexed citations
10.
Kokorovic, Andrea, Sharada Mokkapati, Vikram M. Narayan, et al.. (2020). PD42-08 NOVEL COMBINATION THERAPY USING LENTIVIRAL INTERFERON AND IMMUNE CHECKPOINT BLOCKADE FOR TREATMENT OF BLADDER CANCER IN A MURINE MODEL. The Journal of Urology. 203(Supplement 4). 1 indexed citations
11.
Choi, Woonyoung, Sharada Mokkapati, Debasish Sundi, et al.. (2019). Inhibition of urothelial carcinoma through targeted type I interferon-mediated immune activation. OncoImmunology. 8(5). e1577125–e1577125. 10 indexed citations
12.
Leinonen, Hanna, Igor Oruetxebarria, Haritha Samaranayake, et al.. (2019). Preclinical Proof-of-Concept, Analytical Development, and Commercial Scale Production of Lentiviral Vector in Adherent Cells. Molecular Therapy — Methods & Clinical Development. 15. 63–71. 19 indexed citations
13.
Mokkapati, Sharada, Vikram M. Narayan, Michael Metcalfe, et al.. (2019). Lentiviral interferon: A novel method for gene therapy in bladder cancer.. Journal of Clinical Oncology. 37(7_suppl). 456–456. 1 indexed citations
14.
Mokkapati, Sharada, Kimberly S. Schluns, David J. McConkey, et al.. (2018). The development of interferon-based gene therapy for BCG unresponsive bladder cancer: from bench to bedside. World Journal of Urology. 37(10). 2041–2049. 20 indexed citations
15.
Ylä‐Herttuala, Seppo, et al.. (2018). Up-regulation of Mismatch Repair Pathway by Suicide Gene Therapy: Implications on the use of Temozolomide Treatment in Malignant Glioma. Journal of Cancer Science & Therapy. 10(8). 1 indexed citations
16.
Boorjian, Stephen A., Neal D. Shore, Daniel Canter, et al.. (2017). Intravesical rad-IFNα/Syn3 for patients with high-grade, bacillus Calmette-Guérin (BCG) refractory or relapsed non-muscle invasive bladder cancer: A phase II randomized study.. Journal of Clinical Oncology. 35(6_suppl). 279–279. 1 indexed citations
17.
Valonen, Piia, Janne Weisell, Hanna P. Lesch, et al.. (2016). 706. Consistent Viral Vector Manufacturing for Phase III Using iCELLis 500 Fixed-Bed Technology. Molecular Therapy. 24. S279–S279. 2 indexed citations
18.
Lesch, Hanna P., et al.. (2015). Process Development of Adenoviral Vector Production in Fixed Bed Bioreactor: From Bench to Commercial Scale. Human Gene Therapy. 26(8). 560–571. 34 indexed citations
19.
Wirth, Thomas, Nigel Parker, & Seppo Ylä‐Herttuala. (2013). History of gene therapy. Gene. 525(2). 162–169. 406 indexed citations
20.
Turunen, Mikko P., et al.. (2011). Epigenetherapy, a new concept. BioMolecular Concepts. 2(3). 127–134. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anais K. Amaya Breakdown of academic impact, for papers by Wenxin Cai Breakdown of academic impact, for papers by Jamie L. Shirley Breakdown of academic impact, for papers by Alireza Shahryari Breakdown of academic impact, for papers by Natalie J Ward Breakdown of academic impact, for papers by Giang N. Nguyen Breakdown of academic impact, for papers by Heechung Kwon Breakdown of academic impact, for papers by Giulia Pavani Breakdown of academic impact, for papers by Mark Lyons Breakdown of academic impact, for papers by Cinnamon L Hardee
Rankless by CCL
2026